Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.10 Insider Own50.46% Shs Outstand70.34M Perf Week-0.84%
Market Cap1.41B Forward P/E- EPS next Y-0.14 Insider Trans-0.19% Shs Float34.84M Perf Month8.99%
Income-6.69M PEG- EPS next Q-0.10 Inst Own50.18% Short Float7.91% Perf Quarter25.63%
Sales248.75M P/S5.66 EPS this Y-106.61% Inst Trans-0.13% Short Ratio6.34 Perf Half Y10.86%
Book/sh5.76 P/B3.47 EPS next Y15.99% ROA-1.42% Short Interest2.76M Perf Year49.25%
Cash/sh2.86 P/C7.00 EPS next 5Y- ROE-1.70% 52W Range10.29 - 20.94 Perf YTD14.03%
Dividend Est.- P/FCF- EPS past 5Y- ROI-1.61% 52W High-4.49% Beta0.26
Dividend TTM- Quick Ratio4.31 Sales past 5Y117.81% Gross Margin67.07% 52W Low94.36% ATR (14)0.70
Dividend Ex-Date- Current Ratio4.79 EPS Y/Y TTM-104.65% Oper. Margin-7.73% RSI (14)58.99 Volatility2.41% 3.44%
Employees220 Debt/Eq0.03 Sales Y/Y TTM40.50% Profit Margin-2.69% Recom1.00 Target Price27.40
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q-106.21% Payout0.00% Rel Volume0.49 Prev Close19.72
Sales Surprise3.86% EPS Surprise-20.63% Sales Q/Q-32.37% EarningsFeb 28 BMO Avg Volume435.14K Price20.00
SMA204.84% SMA506.94% SMA20019.97% Trades Volume214,144 Change1.42%
Date Action Analyst Rating Change Price Target Change
Jun-29-20Reiterated BofA Securities Buy $25 → $40
Apr-01-20Initiated BofA/Merrill Buy $25
Mar-11-19Initiated Barclays Overweight $26
Dec-12-18Reiterated Wedbush Outperform $31 → $33
Jun-19-18Initiated JMP Securities Mkt Outperform $33
Feb-21-24 04:01PM
Feb-12-24 09:55AM
Jan-23-24 09:55AM
08:46AM Loading…
Jan-09-24 08:46AM
Jan-04-24 07:30AM
Jan-02-24 04:01PM
Dec-23-23 09:00AM
Dec-15-23 02:30PM
Nov-24-23 02:05PM
Nov-20-23 09:55AM
Nov-09-23 10:01PM
Nov-01-23 08:27AM
Oct-31-23 10:48PM
08:50AM Loading…
Oct-24-23 04:01PM
Oct-20-23 12:08PM
Sep-29-23 12:43PM
Aug-27-23 08:40AM
Aug-22-23 08:14AM
Aug-18-23 09:04PM
Aug-10-23 10:33PM
Aug-07-23 06:14AM
Jul-25-23 10:05PM
Jul-24-23 08:31AM
04:01PM Loading…
Jul-18-23 04:01PM
Jul-17-23 08:00AM
Jul-04-23 08:24PM
Jun-06-23 04:01PM
May-03-23 06:14AM
May-02-23 08:45AM
May-01-23 04:01PM
Apr-09-23 09:21AM
Apr-05-23 01:40PM
Mar-31-23 09:35AM
Mar-30-23 02:20PM
Mar-29-23 10:13AM
Mar-27-23 12:04PM
Mar-23-23 02:25PM
Mar-03-23 06:57PM
Feb-28-23 11:25AM
Feb-27-23 04:01PM
Feb-23-23 10:50AM
Jan-25-23 02:52AM
Jan-21-23 04:51PM
Jan-09-23 08:00AM
Jan-03-23 04:01PM
Nov-30-22 04:01PM
Nov-23-22 04:01PM
Nov-10-22 09:40AM
Nov-07-22 09:55AM
Nov-01-22 09:15AM
Oct-31-22 04:01PM
Oct-24-22 09:40AM
Oct-05-22 08:50AM
Sep-21-22 12:00PM
Sep-20-22 10:30AM
Sep-12-22 08:30AM
Aug-22-22 09:55AM
Aug-05-22 09:55AM
Aug-04-22 09:09AM
Aug-03-22 04:01PM
Aug-02-22 04:01PM
Jul-22-22 12:00PM
Jun-22-22 09:14AM
Jun-19-22 09:49AM
May-05-22 06:52AM
May-03-22 09:15AM
May-02-22 04:01PM
Apr-13-22 09:08AM
Feb-22-22 09:15AM
Feb-18-22 04:01PM
Jan-10-22 08:00AM
Jan-03-22 04:01PM
Dec-31-21 10:00AM
Dec-29-21 09:37AM
Dec-28-21 07:40AM
Dec-01-21 10:00AM
Nov-23-21 04:01PM
Nov-19-21 10:18AM
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ragosa MarkCHIEF FINANCIAL OFFICERJan 03Option Exercise8.8312,000105,96027,632Jan 04 04:30 PM
Ragosa MarkCHIEF FINANCIAL OFFICERJan 03Sale20.0012,000240,00015,632Jan 04 04:30 PM
Megna Michael RCHIEF ACCOUNTING OFFICERJan 02Option Exercise13.8816,670231,38033,675Jan 04 04:30 PM
Megna Michael RCHIEF ACCOUNTING OFFICERJan 02Sale19.1716,670319,56417,005Jan 04 04:30 PM
Megna Michael RCHIEF ACCOUNTING OFFICERDec 19Option Exercise13.889,316129,30626,321Dec 21 04:26 PM
Megna Michael RCHIEF ACCOUNTING OFFICERDec 19Sale19.139,316178,21517,005Dec 21 04:26 PM
Paolini John F.CHIEF MEDICAL OFFICERDec 07Option Exercise1.8628,60053,19673,492Dec 11 04:20 PM
Paolini John F.CHIEF MEDICAL OFFICERDec 07Sale17.6528,600504,75844,892Dec 11 04:20 PM
Paolini John F.CHIEF MEDICAL OFFICERSep 05Option Exercise1.8640074445,292Sep 06 07:03 PM
Paolini John F.CHIEF MEDICAL OFFICERSep 05Sale17.534007,01244,892Sep 06 07:03 PM
Paolini John F.CHIEF MEDICAL OFFICERJul 25Option Exercise1.8629,00053,94070,910Jul 27 04:30 PM
Paolini John F.CHIEF MEDICAL OFFICERJul 25Sale19.1429,000555,16041,910Jul 27 04:30 PM